Biopharma deal value totaled $18.05 billion in March 2026, a pullback from $30.01 billion recorded in February and $31.16 billion in January, but broadly in line with prior years. The March total exceeds March 2024 ($8.5 billion) and is comparable to March 2023 ($19.68 billion) and 2022 ($15.35 billion). For the first quarter (Q1) 2026, deal value increased 17% year over year to $79.22 billion, up from $67.6 billion in Q1 2025.